HONG KONG – Aspiring South Korean pharmaceutical companies had a reality check when Hanmi Pharmaceutical Co. Ltd. faced an abrupt end in its license deal with German pharma giant Boehringer Ingelheim GmbH.
HONG KONG – South Korean drugmaker Celltrion Inc.'s Inflectra (infliximab-dyyb) will begin shipments to the U.S. by late November, making it the first biosimilar monoclonal antibody marketed in the U.S.
HONG KONG – Aspiring South Korean pharmaceutical companies had a reality check when Hanmi Pharmaceutical Co. Ltd. faced an abrupt end in its license deal with German pharma giant Boehringer Ingelheim GmbH.
HONG KONG – Dipping a rather large toe into the diabetes market, Chinese biopharmaceutical company 3Sbio Inc. (HKEX:1530) will pay as much as $100 million for exclusive rights to market two of Astrazeneca plc's diabetes products in China.
HONG KONG – It's no secret that China guards its domestic manufacturers from outside competition through protectionist policies, forcing multinational companies to play by its rules. But things took a slight turn in mid-September.
HONG KONG – Dipping a rather large toe into the diabetes market, Chinese biopharmaceutical company 3Sbio Inc. (HKEX:1530) will pay as much as $100 million for exclusive rights to market two of Astrazeneca plc's diabetes products in China.
